Xenetic appoints Jeffrey Eisenberg as COO
Mr. Eisenberg is a life science executive with over 20 years of operational experience who has been serving on Xenetic’s Board of Directors since July 2016.
Over the course of his career, Mr. Eisenberg has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management.
Prior to joining the Xenetic management team, Mr. Eisenberg has served on the Company’s Board of Directors since July 2016.
Previously, he served at Noven Pharmaceuticals, Inc. for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors.
As CEO, Mr. Eisenberg led Noven to achieve several notable accomplishments including managing the integration of Noven and Hisamitsu following the acquisition of Noven in 2009.
He also served as Senior Vice President of Strategic Alliances, Interim President and CEO, and Executive Vice President while serving at Noven.
Currently, Mr. Eisenberg serves as a member of the Board of Directors of Mabvax Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer.
Mr. Eisenberg graduated from The Wharton School, University of Pennsylvania with his Bachelor of Science degree in Economics and received his Doctor of Law degree from Columbia University Law School in New York. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST